Terapevt Arkh
-
Randomized Controlled Trial Multicenter Study
[New medical technologies in cough therapy: results of a double-blind randomized placebo-controlled multicenter clinical trial].
To study the efficacy and safety of Eladis® in comparison with placebo in patients with non-productive cough. ⋯ The results of the study demonstrate the overall efficacy and statistically significant superiority of Eladis® over placebo: there were significant differences between the study groups in the proportion of patients who decreased the coughing attack frequency by ≥50% by day 5 (p<0.0001). In addition, the clinical cure of cough in the Eladis® group occurred 2 days earlier: the median time was 6 days, vs 8 days in placebo group. There was a decrease in the frequency of cough attacks and a decrease in its severity by more than 3.5 points by day 5 of treatment. All the effects were associated with high safety of the drug.